Clinical Trial
A Study of CART-PSMA-TGFßRDN in Patients With Metastatic Castration Resistant Prostate Cancer
Investigator
Complete title:
CART-PSMA-TGFßRDN-02 A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients with Metastatic Castration Resistant Prostate Cancer
Trial phase:
Phase
I
Study ID:
NCT04227275
Local study ID:
10299
Summary:
Multi-center, open-label, Phase 1 study of the safety, tolerability and feasibility of dosing patients harboring metastatic castration resistant prostate cancer (mCRPC) with genetically modified autologous T cells (CART-PSMA-TGFßRDN cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) and activating the T cell.
Trial keywords:
Prostate Cancer, Castration-resistant (CRPC)
Enrollment status:
Recruiting
Trial eligibility
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Other eligibility criteria may apply.
Trial exclusions
Other exclusion criteria may apply.
Learn more
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact us
